Combination therapy, including adjuvant and neoadjuvant approaches, has become a cornerstone in lung cancer management, offering significant benefits before, during, and after primary treatment.

Learn about adjuvant therapy in lung cancer treatment, its benefits, and one survivor's journey. Discover hope through advancing research. 

[…] coming years. The right treatment for you depends on several factors, including the stage of your cancer, your overall health, and how your cancer responds to initial therapy. Your oncology team, which may include medical oncologists, radiation oncologists, thoracic surgeons, radiologists, and pathologists, will work with you to create an individualized treatment plan. What […]

adjuvant and neoadjuvant therapies

Tagrisso as adjuvant therapy for non-small cell lung cancer approved by the FDA for patients who have had tumor resection.

New clinical trial shows improved survival rates and reduced risk of recurrence in patients taking a targeted therapy for NSCLC.

Nivolumab, alone or with Ipilimumab, is an
FDA-approved immunotherapy option or combination to treat many types of non-small cell lung cancer (NSCLC). It is used: As first-line therapy with ipilimumab in adults whose cancer is metastatic and has the PD-L1 protein but does not have mutations in the EGFR or ALK gene. As first-line therapy […]

[…] the immune system attacking cancer cells. It's used for NSCLC that has: Spread to other parts of the body A protein called PD-L1 No changes in genes called EGFR or ALK   Ipilimumab can be used: As a first treatment for some patients With other cancer drugs called chemotherapy Before surgery (neo- adjuvant) for early-stage NSCLC

[…] is ALK-positive and has metastasized (spread to other parts of the body). FDA approved alectinib (Alecensa) for people with non-small cell lung cancer (NSCLC) who have ALK-positive tumors that can be removed with surgery. Based on the ALINA trial results, the Food and Drug Administration (FDA) approved alectinib as adjuvant therapy for people with ALK-positive NSCLC.

[…] fancied herself a poster child for early detection. And for many years, she was. An Ongoing Battle Against a Recurring Diagnosis After undergoing surgery then, as an adjuvant therapy, Jill spent 15 months on a targeted therapy for EGFR+. Despite the availability of a clinical trial, its location halfway across the country made it impossible […]

[…] every 3 weeks (three cycles) vs the same chemotherapy schedule. Then, patients underwent radiologic staging and surgery within 6 weeks of neoadjuvant therapy. They had the option of adjuvant therapy with or without radiation therapy. An exploratory arm of nivolumab plus ipilimumab was closed early. The primary endpoint was pathologic complete response by blinded independent review, […]